An investigation has uncovered alarming issues including increased mortality rates, absent safety records, dubious efficacy, ...

A startling investigation has revealed a troubling story behind donanemab's approval -- one of questionable data, potential ...

Stocks to Watch. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the ...

A report published Wednesday in The BMJ questioned the safety and effectiveness of the Alzheimer’s disease drug Kisunla ...

A new drug for Alzheimer’s disease is causing excitement despite excess deaths, missing safety data, questionable efficacy, and financial conflicts of interest among the “independent” advisory ...

Eli Lilly's Kisunla (donanemab) has been approved in Japan for early symptomatic Alzheimer's, including mild cognitive ...

The safety and effectiveness of donanemab - an Alzheimer's drug recently approved by the US Food & Drug Administration (FDA) - is called into question in an investigation published by The BMJ today.

Over the past 50 years, the percentage of the Down syndrome population aged 50 and older quadrupled from about 5% to nearly 20% of the population by 2020. Alzheimer's disease prevalence is roughly six ...

Japan's health ministry has officially approved the domestic production and sale of a new drug for Alzheimer's disease.

Eli Lilly said on Tuesday Japan's health ministry has approved donanemab, its drug for Alzheimer's disease, providing ...

The Ministry of Health, Labour and Welfare Japan has approved Kisunla™ (donanemab-azbt, 350 mg/20 mL every four weeks ...

Lilly continues to study donanemab in multiple clinical trials, including TRAILBLAZER-ALZ 3, which is focused on preventing symptomatic Alzheimer's disease in participants with preclinical AD ...